NCT07229261 MitoQ to Improve Vascular Funciton in Preeclampsia
| NCT ID | NCT07229261 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical College of Wisconsin |
| Condition | Preeclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-03-18 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with preeclampsia could translate into a viable therapeutic option.
Eligibility Criteria
Inclusion Criteria: * Inpatient Cohort * pregnant patients with a clinical diagnosis of preeclampsia with severe features * gestational age between 23+0 and 32+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features * Able to consent and follow a 2-step commend * English speaking * Outpatient Cohort * Pregnant patients with a clinical diagnosis of preeclampsia without severe features * gestational age between 23+0 and 34+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery * Planned outpatient management of preeclampsia * Able to consent and follow a 2-step commend * English speaking Exclusion Criteria: * • Unable to stand from chair without physical assistance from another person (able to use assistive device). * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization) * History of head trauma or concussion within the past 6 months * Comorbid neurological disorder * Peripheral vascular disease * Diagnosed myocardial infarction or arrhythmia in the previous year * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Contact & Investigator
Jennifer J McIntosh, D.O.,
PRINCIPAL INVESTIGATOR
Medical College of Wisconsin
Frequently Asked Questions
Who can join the NCT07229261 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Preeclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07229261 currently recruiting?
Yes, NCT07229261 is actively recruiting participants. Contact the research team at jmcintosh@mcw.edu for enrollment information.
Where is the NCT07229261 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT07229261 clinical trial?
NCT07229261 is sponsored by Medical College of Wisconsin. The principal investigator is Jennifer J McIntosh, D.O., at Medical College of Wisconsin. The trial plans to enroll 80 participants.